GlassScriptPhysician profile
Aliya Yasin
NPI 1841266061
$557.75
in general payments reported to CMS, 2019-2025
14 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $37.57 · 2022: $55.93 · 2023: $42.06 · 2024: $109 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $124.54 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $77.73 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi Pasteur INC. | $60.96 | 2022-2024 | |
| Cranial Technologies, INC | $56.58 | 2020-2024 | Doc Band |
| Phadia US INC. | $41.59 | 2019 | |
| Glaxosmithkline, LLC. | $25.83 | 2024 | Rotarix, Pediarix, Bexsero |
| Mirum Pharmaceuticals, INC. | $25.29 | 2025 | Livmarli |
| Alk-Abello, INC | $24.47 | 2025 | Grastek, Odactra, Ragwitek |
| Astrazeneca Pharmaceuticals LP | $23.50 | 2024 | Flumist Quadrivalent |
| Pfizer INC. | $22.20 | 2019 | |
| Tris Pharma INC | $20.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.50 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.27 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Yasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.